期刊
SEMINARS IN IMMUNOPATHOLOGY
卷 31, 期 3, 页码 411-419出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00281-009-0166-3
关键词
Hematopoietic stem cell; Hepatocytes; Cell fusion; Aldehyde dehydrogenase; Liver damage; Regenerative medicine
资金
- NIDDK [R01DK61848]
- NHLBI [R01HL073256]
- Office of the Dean of the UC Davis School of Medicine
- NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026825] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073256] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053041, R21DK062892, R01DK061848] Funding Source: NIH RePORTER
Immune-deficient mouse models of liver damage allow examination of human stem cell migration to sites of damage and subsequent contribution to repair and survival. In our studies, in the absence of a selective advantage, transplanted human stem cells from adult sources did not robustly become hepatocytes, although some level of fusion or hepatic differentiation was documented. However, injected stem cells did home to the injured liver tissue and release paracrine factors that hastened endogenous repair and enhanced survival. There were significantly higher levels of survival in mice with a toxic liver insult that had been transplanted with human stem cells but not in those transplanted with committed progenitors. Transplantation of autologous adult stem cells without conditioning is a relatively safe therapy. Adult stem cells are known to secrete bioactive factors that suppress the local immune system, inhibit fibrosis (scar formation) and apoptosis, enhance angiogenesis, and stimulate recruitment, retention, mitosis, and differentiation of tissue-residing stem cells. These paracrine effects are distinct from the direct differentiation of stem cells to repair tissue. In patients at high risk while waiting for a liver transplant, autologous stem cell therapy could be considered, as it could delay the decline in liver function.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据